CA3044270A1 - The use of trimetazidine in the prevention and/or treatment of contrast-induced acute kidney injury____ - Google Patents

The use of trimetazidine in the prevention and/or treatment of contrast-induced acute kidney injury____ Download PDF

Info

Publication number
CA3044270A1
CA3044270A1 CA3044270A CA3044270A CA3044270A1 CA 3044270 A1 CA3044270 A1 CA 3044270A1 CA 3044270 A CA3044270 A CA 3044270A CA 3044270 A CA3044270 A CA 3044270A CA 3044270 A1 CA3044270 A1 CA 3044270A1
Authority
CA
Canada
Prior art keywords
pharmaceutically acceptable
acceptable salt
trimetazidine
patient
administered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3044270A
Other languages
English (en)
French (fr)
Inventor
Anna Kazanchyan
Shalini CORNELIO
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Saghmos Therapeutics Inc
Original Assignee
Saghmos Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Saghmos Therapeutics Inc filed Critical Saghmos Therapeutics Inc
Publication of CA3044270A1 publication Critical patent/CA3044270A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CA3044270A 2016-11-21 2017-11-21 The use of trimetazidine in the prevention and/or treatment of contrast-induced acute kidney injury____ Pending CA3044270A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662424771P 2016-11-21 2016-11-21
US62/424,771 2016-11-21
PCT/US2017/062771 WO2018094387A1 (en) 2016-11-21 2017-11-21 Prevention and/or treatment of contrast-induced acute kidney injury

Publications (1)

Publication Number Publication Date
CA3044270A1 true CA3044270A1 (en) 2018-05-24

Family

ID=62144125

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3044270A Pending CA3044270A1 (en) 2016-11-21 2017-11-21 The use of trimetazidine in the prevention and/or treatment of contrast-induced acute kidney injury____

Country Status (6)

Country Link
US (4) US11123345B2 (enExample)
EP (2) EP3525771A4 (enExample)
JP (4) JP7474463B2 (enExample)
CA (1) CA3044270A1 (enExample)
MX (1) MX2019005782A (enExample)
WO (1) WO2018094387A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3525771A4 (en) * 2016-11-21 2020-05-27 Saghmos Therapeutics, Inc. PREVENTION AND / OR TREATMENT OF ACUTE RENAL FAILURE INDUCED BY CONTRAST AGENTS
EP3755329A4 (en) * 2018-02-19 2021-10-27 Martin Pharmaceuticals, Inc. STABLE LIQUID FORMULATION OF TRIMETAZIDINE FOR ORAL USE
WO2025137462A1 (en) * 2023-12-21 2025-06-26 Numiera Therapeutics Inc. Combination therapy for cancer

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2490963B1 (fr) * 1980-09-30 1986-04-18 Science Union & Cie Nouvelle composition therapeutique a action anti-ischemique contenant de la trimethoxy 2, 3, 4-benzyl 1-piperazine
US20080059228A1 (en) 2004-04-24 2008-03-06 Christopher Bossi Operation Of A Remote Medication Management System
US20100266501A1 (en) * 2006-11-07 2010-10-21 University Of Vermont and State Agricltural College Methods and compositions for organ protection
CN101702884A (zh) 2007-03-09 2010-05-05 西姆科皮亚公司 用于治疗高血糖症及相关病症的脂肪酸氧化抑制剂
WO2009066315A2 (en) * 2007-08-08 2009-05-28 Usv Limited Sustained release compositions of trimetazidine and process for preparation thereof
WO2009034541A2 (en) 2007-09-11 2009-03-19 Ranbaxy Laboratories Limited Controlled release pharmaceutical dosage forms of trimetazidine
US20090257999A1 (en) * 2007-12-31 2009-10-15 Inotek Pharmaceuticals Corporation Method of preventing contrast-induced nephropathy
CN107802821A (zh) * 2008-02-26 2018-03-16 康奈尔大学 用于防止和治疗急性肾损伤的方法
CA2776452A1 (en) 2009-10-02 2011-04-07 Baxter International Inc. Hematopoietic stem cells for use in the treatment of a kidney injury
US9271952B2 (en) * 2011-10-11 2016-03-01 Complexa, Inc. Compositions and methods for treating nephropathy
FR2986431B1 (fr) * 2012-02-03 2017-03-17 Servier Lab Composition pharmaceutique a liberation prolongee de trimetazidine, son procede de fabrication et son utilisation dans des traitements therapeutiques
CN103735550B (zh) 2013-12-25 2015-11-18 上海市闸北区中心医院 一种治疗慢性肾脏病心肌损伤的药物组合物及其应用
EP3525771A4 (en) 2016-11-21 2020-05-27 Saghmos Therapeutics, Inc. PREVENTION AND / OR TREATMENT OF ACUTE RENAL FAILURE INDUCED BY CONTRAST AGENTS
WO2018129045A1 (en) 2017-01-03 2018-07-12 Saghmos Therapeutics, Inc. Methods of improving patient compliance to treat contrast-induced injury

Also Published As

Publication number Publication date
US11123345B2 (en) 2021-09-21
JP7474463B2 (ja) 2024-04-25
JP2022059054A (ja) 2022-04-12
US20250073227A1 (en) 2025-03-06
MX2019005782A (es) 2019-08-29
US12678435B2 (en) 2026-07-14
JP2026069729A (ja) 2026-04-23
JP2024028652A (ja) 2024-03-04
EP3525771A1 (en) 2019-08-21
WO2018094387A1 (en) 2018-05-24
US20180140599A1 (en) 2018-05-24
EP4378457A3 (en) 2024-07-31
JP7896852B2 (ja) 2026-07-29
EP3525771A4 (en) 2020-05-27
US11986473B2 (en) 2024-05-21
JP2019535830A (ja) 2019-12-12
US20190365740A1 (en) 2019-12-05
US20210401832A1 (en) 2021-12-30
EP4378457A2 (en) 2024-06-05

Similar Documents

Publication Publication Date Title
US20250073227A1 (en) Prevention and/or treatment of contrast-induced acute kidney injury
RS53491B1 (sr) Kompozicije za lečenje centralno posredovane mučnine i povraćanja
EA015122B1 (ru) Фармацевтическая композиция и ее применение для лечения тромбоза
US20040024013A1 (en) Medicinal compositions containing aspirin
US20250099466A1 (en) Milvexian for prevention and treatment of thromboembolic disorders
JP2014534270A5 (enExample)
HK1217435A1 (zh) 药物组合物
JP2018531605A5 (enExample)
SK288707B6 (sk) Farmaceutické kombinácie obsahujúce antagonistu P2T receptora a ďalšie antitrombotické činidlá, spôsob ich prípravy a ich použitie na liečenie a prevenciu trombózy
KR20120138229A (ko) 정맥내 투여용 이부프로펜을 이용한 중증 환자의 치료
KR20120089623A (ko) 정맥내 투여용 이부프로펜을 이용한 환자의 치료
HK40112570A (en) Prevention and/or treatment of contrast-induced acute kidney injury
JP7618235B2 (ja) ｐ－ボロノフェニルアラニンを含有する注射液剤の析出防止方法
WO2022147318A1 (en) Methods of treatment
JP2024502821A5 (enExample)
US20110117070A1 (en) Compositions and methods for treating headache
CA2612315A1 (en) Dosage regimen for prasugrel
WO2018129045A1 (en) Methods of improving patient compliance to treat contrast-induced injury
EP4185291B1 (en) Low dose regimen and formulation of a 5-methyl-1,2,4-oxadiazol-3-yl compound
JP2009538822A5 (enExample)
JP2016510738A5 (enExample)
Vet—QC09CA02 Eprosartan Mesilate (BANM, rINNM)
Rahman A clinically oriented review of the landmark clinical trials comparing warfarin and aspirin to novel oral anticoagulants in atrial fibrillation
HK40084518B (en) Low dose regimen and formulation of a 5-methyl-1,2,4-oxadiazol-3-yl compound
HK40084518A (en) Low dose regimen and formulation of a 5-methyl-1,2,4-oxadiazol-3-yl compound

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20220921

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 7TH ANNIV.) - STANDARD

Year of fee payment: 7

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20241023

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20241023

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20241023

D15 Examination report completed

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT

Effective date: 20241230

T11 Administrative time limit extension requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-T10-T11-T100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXTENSION OF TIME FOR TAKING ACTION REQUEST RECEIVED

Effective date: 20250423

B12 Application deemed to be withdrawn, abandoned or lapsed

Free format text: ST27 STATUS EVENT CODE: N-2-6-B10-B12-B303 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: DEEMED ABANDONED - FAILURE TO RESPOND TO AN EXAMINER'S REQUISITION

Effective date: 20250630

T13 Administrative time limit extension granted

Free format text: ST27 STATUS EVENT CODE: A-2-2-T10-T13-T101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXTENSION OF TIME FOR TAKING ACTION REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20250820

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20250820

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 8TH ANNIV.) - STANDARD

Year of fee payment: 8

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20251022

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20251022

C11 Application revival requested

Free format text: ST27 STATUS EVENT CODE: N-6-6-C10-C11-C106 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REINSTATEMENT REQUEST RECEIVED

Effective date: 20260625

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: N-6-6-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION

Effective date: 20260625

C13 Application revived following an application revival request

Free format text: ST27 STATUS EVENT CODE: A-6-2-C10-C13-C102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REINSTATEMENT REQUIREMENTS DEEMED COMPLIANT FOR ALL ABANDONMENT REASONS

Effective date: 20260629

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20260629

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20260629

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260629

Free format text: ST27 STATUS EVENT CODE: N-6-6-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20260629